IL116511A0 - Mutant enzymes - Google Patents

Mutant enzymes

Info

Publication number
IL116511A0
IL116511A0 IL11651195A IL11651195A IL116511A0 IL 116511 A0 IL116511 A0 IL 116511A0 IL 11651195 A IL11651195 A IL 11651195A IL 11651195 A IL11651195 A IL 11651195A IL 116511 A0 IL116511 A0 IL 116511A0
Authority
IL
Israel
Prior art keywords
enzyme
host
prodrug
component
natural
Prior art date
Application number
IL11651195A
Other languages
English (en)
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL116511(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of IL116511A0 publication Critical patent/IL116511A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • External Artificial Organs (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
IL11651195A 1994-12-23 1995-12-22 Mutant enzymes IL116511A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds

Publications (1)

Publication Number Publication Date
IL116511A0 true IL116511A0 (en) 1996-07-23

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11651195A IL116511A0 (en) 1994-12-23 1995-12-22 Mutant enzymes

Country Status (23)

Country Link
US (1) US5985281A (no)
EP (1) EP0806964B1 (no)
JP (1) JP3805365B2 (no)
KR (1) KR100270650B1 (no)
CN (1) CN1095677C (no)
AT (1) ATE222124T1 (no)
AU (1) AU701916B2 (no)
BR (1) BR9510490B1 (no)
CA (1) CA2205091A1 (no)
CZ (1) CZ195297A3 (no)
DE (1) DE69527805T2 (no)
ES (1) ES2181805T3 (no)
FI (1) FI972683A (no)
HU (1) HUT77450A (no)
IL (1) IL116511A0 (no)
MX (1) MX9704575A (no)
NO (1) NO972882L (no)
NZ (1) NZ297529A (no)
PL (1) PL184031B1 (no)
RU (1) RU2189251C2 (no)
SK (1) SK80997A3 (no)
TR (1) TR199501654A2 (no)
WO (1) WO1996020011A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU707689B2 (en) * 1995-08-16 1999-07-15 Astrazeneca Ab Mutated Carboxypeptidase B enzyme conjugated to a tumour targeted antibody for use in Antibody Directed Enzyme Prodrug Therapy
TW406454B (en) 1996-10-10 2000-09-21 Berg Tech Inc High density connector and method of manufacture
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
CA2344440A1 (en) * 1998-09-18 2000-03-30 Immunomedics, Inc. Antibody directed enzyme prodrug therapy (edept) with glucoronidase
KR20020073127A (ko) * 1999-09-17 2002-09-19 겐자임 트랜스제닉스 코포레이션 형질전환에 의하여 생성된 융합 단백질
AU2003298787A1 (en) * 2002-11-27 2004-06-23 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
DK1945666T3 (da) * 2005-10-21 2013-07-01 Genzyme Corp Antistoffer med forøget antistofafhængig cellulær cytotoksicitetsaktivitet, fremgangsmåder til fremstilling af disse og anvendelse heraf
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2037954A4 (en) * 2006-06-20 2011-09-14 Janssen Pharmaceutica Nv METHOD FOR MODULATING PHARMACOKINETICS AND METABOLISM OF THERAPEUTIC USE
WO2008041059A1 (en) 2006-10-03 2008-04-10 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
EP2279003A4 (en) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF INFLAMMATORY DISEASES
US10745492B1 (en) 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
ATE123414T1 (de) * 1989-01-23 1995-06-15 Akzo Nobel Nv Ortspezifische in-vivo-aktivierung von therapeutischen arzneimitteln.
EP0625205A1 (en) * 1992-01-30 1994-11-23 Genzyme Limited Chiral synthesis with modified enzymes
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Also Published As

Publication number Publication date
US5985281A (en) 1999-11-16
WO1996020011A1 (en) 1996-07-04
EP0806964B1 (en) 2002-08-14
BR9510490B1 (pt) 2010-10-05
AU4269796A (en) 1996-07-19
FI972683A0 (fi) 1997-06-19
SK80997A3 (en) 1998-02-04
CZ195297A3 (en) 1997-12-17
CA2205091A1 (en) 1996-07-04
TR199501654A2 (tr) 1996-07-21
CN1171054A (zh) 1998-01-21
NO972882L (no) 1997-08-19
AU701916B2 (en) 1999-02-11
MX9704575A (es) 1997-10-31
JPH10511547A (ja) 1998-11-10
BR9510490A (pt) 1998-01-13
CN1095677C (zh) 2002-12-11
NZ297529A (en) 1999-07-29
PL184031B1 (pl) 2002-08-30
FI972683A (fi) 1997-06-19
ES2181805T3 (es) 2003-03-01
EP0806964A1 (en) 1997-11-19
ATE222124T1 (de) 2002-08-15
TR199501654A3 (no) 1996-07-21
HUT77450A (hu) 1998-04-28
NO972882D0 (no) 1997-06-20
JP3805365B2 (ja) 2006-08-02
DE69527805T2 (de) 2003-04-24
KR100270650B1 (ko) 2000-11-01
PL320964A1 (en) 1997-11-24
DE69527805D1 (de) 2002-09-19
RU2189251C2 (ru) 2002-09-20

Similar Documents

Publication Publication Date Title
IL116511A0 (en) Mutant enzymes
AU7123296A (en) Liposomal formulations of mitoxantrone
PL350658A1 (en) Medical preparations for the treatment of alpha−galactosidase a deficiency
BR9812079A (pt) Salmonella sp. mutante, lipopolissacarìdeo, processo para inibir o crescimento ou reduzir o volume de um câncer de tumor sólido, composição farmacêutica, e, processo aperfeiçoado para selecionar alterações genéticas em uma bactéria.
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
DE69329735T2 (de) Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken
IL132348A0 (en) Gene directed antibody-enzyme prodrug therapy
AU2015195A (en) Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders
CA2232344A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
WO1999032634A3 (en) Compositions derived from mycobacterium vaccae and methods for their use
ZA97657B (en) Ligand directed enzyme prodrug therapy.
AU2002360350A1 (en) Peptides that home to tumor lymphatic vasculature and methods of using same
MX9800967A (es) Compuestos quimicos.
AU1594897A (en) Solid instant-release forms of administration and process for producing the same
AU6182994A (en) Bifunctional glycoproteins having a modified carbohydrate complement, and their use in tumor-selective therapy
AU3991899A (en) Verotoxin b subunit for immunization
WO2001024764A3 (en) Cell targeting compositions and methods of using the same
ZA200107368B (en) Immunostimulant bacterial membrane fractions in cancer treatment
AU6942896A (en) Use of muteins of wild-type cytokines as immunogens
AU3796297A (en) Pituitary differentiation factor and methods of use thereof
MX9802809A (es) Ureasa para el tratamiento de infecciones de helicobacter pylori.
JO1766B1 (en) Effective new compounds
WO1997023607A3 (en) Presentation of antigen, introduced into cells by stimulation of macropinocytosis
TW332816B (en) Peptide and carbohydrate
UA33983A (uk) Спосіб лікування раку передміхурової залози

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees